B1GN34 Stock Overview
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BeiGene, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$42.30 |
| 52 Week High | US$54.55 |
| 52 Week Low | US$27.12 |
| Beta | 0.60 |
| 1 Month Change | -6.75% |
| 3 Month Change | -6.00% |
| 1 Year Change | 20.86% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 24.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| B1GN34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | -1.9% | -2.9% | -3.0% |
| 1Y | 20.9% | -1.9% | -11.7% |
Return vs Industry: B1GN34 exceeded the BR Biotechs industry which returned -1.9% over the past year.
Return vs Market: B1GN34 exceeded the BR Market which returned -11.7% over the past year.
Price Volatility
| B1GN34 volatility | |
|---|---|
| B1GN34 Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in BR Market | 9.5% |
| 10% least volatile stocks in BR Market | 2.8% |
Stable Share Price: B1GN34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine B1GN34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 10,000 | John Oyler | www.beigene.com |
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company’s clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor.
BeiGene, Ltd. Fundamentals Summary
| B1GN34 fundamental statistics | |
|---|---|
| Market cap | R$114.10b |
| Earnings (TTM) | -R$5.00b |
| Revenue (TTM) | R$19.60b |
5.8x
P/S Ratio-22.8x
P/E RatioIs B1GN34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B1GN34 income statement (TTM) | |
|---|---|
| Revenue | CN¥23.51b |
| Cost of Revenue | CN¥3.84b |
| Gross Profit | CN¥19.67b |
| Other Expenses | CN¥25.66b |
| Earnings | -CN¥5.99b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -56.41 |
| Gross Margin | 83.67% |
| Net Profit Margin | -25.50% |
| Debt/Equity Ratio | 29.6% |
How did B1GN34 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 13:56 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BeiGene, Ltd. is covered by 57 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Michael Meng | BOCI Research Ltd. |
| Yonglin Yan | BOCI Research Ltd. |